GlucoTrack settlement: $2 million initial payment to Alto Opportunity Master Fund
GlucoTrack said it entered a settlement agreement related to debt owed to Alto Opportunity Master Fund by Apimeds Pharmaceuticals US. The company will make an initial payment of $2 million and pay another $2 million under the settlement terms.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.